# The Association of Arsenic Metabolism and Blood Pressure: A Cross-Sectional Analysis in the MesoAmerican Nephropathy Occupational Study (MANOS)

## TL;DR

This study found that how the body processes arsenic is linked to higher blood pressure, suggesting that arsenic metabolism could be important for assessing cardiovascular risk.

## Contribution

The study is among the first to investigate the association between arsenic metabolism and specific blood pressure outcomes using multiple modeling approaches.

## Key findings

- Higher dimethylated arsenic (DMA%) was associated with increased systolic and pulse pressure.
- Participants with higher monomethylated arsenic (MMA%) showed lower systolic and pulse pressure.
- Efficient methylation of arsenic to DMA was linked to higher blood pressure outcomes.

## Abstract

Growing evidence indicates that arsenic metabolism is associated with cardiometabolic outcomes but few studies have investigated the association of arsenic metabolism with blood pressure outcomes.

We evaluated cross-sectional associations between urinary arsenic metabolites and blood pressure outcomes—systolic and diastolic blood pressure, pulse pressure, and mean arterial pressure—among 393 participants in the MesoAmerican Nephropathy Occupational Study (MANOS) in El Salvador and Nicaragua. We applied three modeling approaches: (1) conventional models assessing each urinary arsenic species [inorganic arsenic (InAs), monomethylated arsenic (MMA), and dimethylated arsenic (DMA)] individually as a percentage of the sum of inorganic and methylated arsenic; (2) leave-one-out models evaluating the relative effects of two species while holding the third constant; and (3) principal components analysis (PCA) representing methylation steps of arsenic metabolism.

In conventional models adjusted for age, body mass index, worksite, pesticide use, smoking status, and water consumption, participants with higher vs. lower DMA% (>77.51% vs. ≤71.28% DMA over the sum of inorganic and methylated arsenic species) showed higher systolic blood pressure (β = 3.75 mmHg; 95% CI: 0.65, 6.85) and pulse pressure (β = 2.57 mmHg; 95% CI: 0.04, 5.10), while participants with higher vs. lower MMA% (>16.07% vs. ≤12.39%) showed lower systolic blood pressure (β = −3.70 mmHg; 95% CI: −6.86, −0.55) and pulse pressure (β = −2.76 mmHg; 95% CI: −5.33, −0.19). In leave-one-out models, higher DMA% (>77.51% vs. <71.28%) as a result of lower MMA%, was associated with higher systolic blood pressure (β = 7.24 mmHg; 95% CI: 2.25, 12.2), pulse pressure (β = 5.29 mmHg; 95% CI: 1.22, 9.36), and mean arterial pressure (β = 3.71 mmHg; 95% CI: −0.08, 7.50). PCA results supported these findings. The second methylation step from MMA to DMA was associated with higher systolic blood pressure (β = 0.93 mmHg; 95% CI: 0.11, 1.75) and pulse pressure (β = 0.74 mmHg; 95% CI: 0.07, 1.40).

Our findings suggest that biomarkers of efficient methylation of inorganic arsenic to DMA are associated with higher blood pressure compared to partial methylation to MMA, highlighting the importance of arsenic metabolism profiles in cardiovascular risk assessment.